New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
08:30 EDTBAYRYFDA says data doesn't support aspirin as defense against first heart attack
The FDA stated in a consumer information communication issued May 2 that it has reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. "In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established," the FDA said. The available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have cardiovascular disease or who have already had a heart attack or stroke, the FDA added, stating that the known benefits of aspirin for secondary prevention outweigh the risk of bleeding in patients who have had a cardiovascular event. “Importantly, the ruling does not impact the numerous cardiovascular indications for which aspirin is already approved by the FDA,” Anne Coiley, a spokeswoman for Bayer, said in an e-mail to Bloomberg. Reference Link
News For BAYRY From The Last 14 Days
Check below for free stories on BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 8, 2014
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
05:37 EDTBAYRYRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
08:07 EDTBAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use